APLS - CIK 0001492422
The table below shows Apellis Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $45.33M | -$87.87M | -$594.74M | -$513.75M | -$563.13M | -$160.49M |
| Capital expenditure | $313.00K | $403.00K | $773.00K | $1.52M | $1.10M | $5.42M |
| Investing cash flow | -$313.00K | -$403.00K | -$674.00K | $59.89M | $247.62M | -$316.99M |
| Dividends paid | - | - | - | - | - |
Apellis Pharmaceuticals, Inc. reported operating cash flow of $45.33M for fiscal year 2025. That is up 151.6% from -$87.87M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$26.00M (FY 2016) to $45.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $8.88M | $149.24M | $394.50M | $365.66M | $392.24M | $692.18M |